Comparative Pharmacology
Head-to-head clinical analysis: ARYMO ER versus ULTRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYMO ER versus ULTRAM.
ARYMO ER vs ULTRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYMO ER (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception. It also activates descending inhibitory pathways.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
15 mg to 30 mg orally every 12 hours; titrate to effect; maximum 60 mg per dose.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in healthy adults. This extended half-life compared to immediate-release morphine (2–4 hours) allows for once-daily dosing. In elderly or hepatic/renal impairment, half-life may be prolonged up to 22 hours.
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
Primarily renal (90%), with approximately 10% excreted unchanged in urine; the remainder as glucuronide conjugates (morphine-3-glucuronide, morphine-6-glucuronide) and minor metabolites. Biliary/fecal excretion accounts for <10%.
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic